Canaccord lowered the firm’s price target on DexCom to $112 from $150 and keeps a Buy rating on the shares. The firm said they delivered strong top line results with another record Q of new patient adds led by the ramping basal and G7 opportunities in the US, and robust bottom-line results driven by continued operating leverage with strong cost control and an increasingly tenured/productive salesforce.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DXCM: